Loading
companiesCompany
LEAH Labs
LEAH Labs makes CAR-T cell therapy for dogs with lymphoma, using virus-free gene editing to bring the cost of a dose down to hundreds of dollars.
Overview
LEAH Labs (LifEngine Animal Health Laboratories) is developing CAR-T cell therapy for dogs with B-cell lymphoma, the naturally occurring counterpart of human non-Hodgkin lymphoma, using a non-viral gene-editing approach that the company says brings manufacturing cost to roughly $500 per dose. Its YC profile reports remissions in dogs with late-stage lymphoma. Veterinary cell therapies are regulated by the USDA rather than the FDA, which the company uses to iterate faster; the stated long-term aim is to carry the platform into human oncology.
Headquarters
Minneapolis, MN, US
Funding
All startupsStartupYC W19
Investors
Type
Stage
Startup · Y Combinator Winter 2019
Website
Similar pages
- CompanyGamgee
Shares Y Combinator and the tags veterinary, comparative-oncology.
- CompanyFidoCure
Shares Y Combinator and the tags veterinary, comparative-oncology.
- CompanyCellogen Therapeutics
Shares CD20, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- CompanyModulari-T
Shares Y Combinator, CAR-T cell therapy.
- CompanyData Driven Bioscience (Duoseq)
- TrialStudy of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Shares CD20, Diffuse large B-cell lymphoma.
- CompanyPoseida Therapeutics
Shares CD20, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- PersonWyndham H. Wilson
Shares CD20, Diffuse large B-cell lymphoma.